Significant events during the first quarter 2024 (Jan – Mar)

• Mentice has received a major repeat order from a world-leading medical technology company.
• Mentice performed its first Capital Market Day on March 21 in Stockholm.
• Mentice presented revised Financial Targets during the Capital Markets Day.

Financial targets
Growth
20-30% annual growth in net sales.
Profitability
To reach a 20% EBITDA margin within three years with a longer-term target of 30%.
 

FIRST QUARTER 2024 (JAN - MAR)

• Order intake amounted to 38 (58) MSEK, a decrease of -34.2%, of which -0.1% was related to the currency effect.
• The order book by the end of the period was 146.9 (126.2) MSEK, an increase of 16,4%.
• Net sales amounted to 45.3 (65.0) MSEK, a decrease of -30%, whereof -28% organic and -2% currency effect.
• Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to -18.4 (7.3) MSEK.
• Net income for the period amounted to -24.6 (-1.5) MSEK.
• Earnings per share (EPS) were -0.96 (-0.06) SEK.
• Cash flow from operating activities amounted to 1.9 (1.2) MSEK.

 
Webcast presentation of the interim report
To join the presentation, please visit https://investor.mentice.com.